Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Javier Garcia-Corbacho"'
Autor:
Mark Stroh, Melissa Lynne Johnson, Henry Castro, Jordi Rodon, Alexander I. Spira, Rachel E. Sanborn, Hirva Mamdani, Nehal Lakhani, Anthony B. El-Khoueiry, Song Wang, Navid Hafez, Valentina Boni, Alison L. Hannah, Javier Garcia-Corbacho
Publikováno v:
Clinical Cancer Research. 27:4521-4530
Purpose: PROCLAIM-CX-2029 is a phase I first-in-human study of CX-2029, a Probody–drug conjugate targeting CD71 (transferrin receptor 1) in adults with advanced solid tumors. Although the transferrin receptor is highly expressed across multiple tum
Autor:
Seock-Ah Im, Kevin Norwood, Donna M. Graham, Hyun Cheol Chung, Esma Saada-Bouzid, Alan D. Smith, Juanita Lopez, Javier Garcia-Corbacho, Carlos Gomez-Roca, Eduardo Castanon, Eduardo Yanez, Federico Longo Muñoz, Corina E. Dutcus, Razi Ghori
Publikováno v:
Cancer Research. 81:PS12-07
Background: Triple-negative breast cancer (TNBC) is associated with poor survival outcomes and treatment options are limited. These tumors lack therapeutic targets and become rapidly resistant to chemotherapy. The anti–PD-1 antibody pembrolizumab s
Autor:
Nitzan Rosenfeld, Christopher Smith, Charles E. Massie, Florent Mouliere, Ioannis Gounaris, Irena Hudecova, Lise Barlebo Ahlborn, Kevin M. Brindle, Christine Parkinson, Grant D. Stewart, Francesco Marass, Pippa Corrie, Richard D. Baird, Mercedes Jimenez-Linan, Dineika Chandrananda, James D. Brenton, Suzanne Murphy, Wendy N. Cooper, Johanna Burge, Matthew D. Eldridge, Anna Supernat, Olga Østrup, Morten Mau-Sørensen, Javier Garcia-Corbacho, Keval M. Patel, Elizabeth Moore, Davina Gale, James Morris, Simon Pacey, Michiel S. van der Heijden, Anna M. Piskorz, Katrin Heider, Jonathan C. M. Wan, Colin Watts, Richard Mair, Susana Ros, Teodora Goranova
Publikováno v:
Science Translational Medicine, 10(466). American Association for the Advancement of Science
Mouliere, F, Chandrananda, D, Piskorz, A M, Moore, E K, Morris, J, Ahlborn, L B, Mair, R, Goranova, T, Marass, F, Heider, K, Wan, J C M, Supernat, A, Hudecova, I, Gounaris, I, Ros, S, Jimenez-Linan, M, Garcia-Corbacho, J, Patel, K, Østrup, O, Murphy, S, Eldridge, M D, Gale, D, Stewart, G D, Burge, J, Cooper, W N, van der Heijden, M S, Massie, C E, Watts, C, Corrie, P, Pacey, S, Brindle, K M, Baird, R D, Mau-Sørensen, M, Parkinson, C A, Smith, C G, Brenton, J D & Rosenfeld, N 2018, ' Enhanced detection of circulating tumor DNA by fragment size analysis ', Science Translational Medicine, vol. 10, no. 466 . https://doi.org/10.1126/scitranslmed.aat4921
Mouliere, F, Chandrananda, D, Piskorz, A M, Moore, E K, Morris, J, Ahlborn, L B, Mair, R, Goranova, T, Marass, F, Heider, K, Wan, J C M, Supernat, A, Hudecova, I, Gounaris, I, Ros, S, Jimenez-Linan, M, Garcia-Corbacho, J, Patel, K, Østrup, O, Murphy, S, Eldridge, M D, Gale, D, Stewart, G D, Burge, J, Cooper, W N, van der Heijden, M S, Massie, C E, Watts, C, Corrie, P, Pacey, S, Brindle, K M, Baird, R D, Mau-Sørensen, M, Parkinson, C A, Smith, C G, Brenton, J D & Rosenfeld, N 2018, ' Enhanced detection of circulating tumor DNA by fragment size analysis ', Science Translational Medicine, vol. 10, no. 466 . https://doi.org/10.1126/scitranslmed.aat4921
Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on genomic alterations but have rarely considered the biological properties of plasma cell-free DNA (cfDNA). We hypothesized that differences in fragment lengths of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d66fbdd69cec53a8010429a60ab38565
Autor:
Sanjeev Gill, Kevin Norwood, Donna M. Graham, Andrew Eugene Hendifar, Nicolas Penel, Peter Kubiak, Mark Doherty, Carlos Gomez-Roca, Daniel Heudobler, Zarnie Lwin, Tae Won Kim, Eduardo Yanez, Hélène Senellart, Federico Longo, Javier Garcia-Corbacho, Luis Villanueva, Corinne Maurice-Dror, Hyun Cheol Chung, Fan Jin, Razi Ghori
Publikováno v:
Journal of Clinical Oncology. 39:321-321
321 Background: Second-line treatment options for patients with biliary tract cancers (BTC) are limited. Lenvatinib, an anti-angiogenic multikinase inhibitor, in combination with the programmed death-1 immune checkpoint inhibitor pembrolizumab, has d
Autor:
Molly C. Hardebeck, Marie Paule Sablin, Francesco Ricci, Marta Capelán, Marta Puig, Aleix Prat, Mingchi Hsu, Javier Garcia-Corbacho, Anthony Gonçalves, Fadi Braiteh, Douglas Yee, Dennis Chin-Lun Huang, Hiroji Iwata, Patricia LoRusso
Publikováno v:
Cancer Research. 80:CT165-CT165
Introduction: Insulin-like growth factor (IGF) signaling and the cyclin D-cyclin-dependent kinase (CDK) 4 & 6-retinoblastoma pathway are implicated in cancer progression and treatment resistance. Activation of the IGF receptor results in upregulation
Autor:
Hans Wildiers, Martine Piccart-Gebhart, Manuel Ruiz Borrego, Valentina Boni, Nicolas Isambert, Cecilia Simonelli, Begona Jimenez-Rodriguez, Philippe Aftimos, Andrea Pellacani, Cristina Saura, Diego Tosi, Bernard Doger, Andrew M Wardley, François Duhoux, Hendrik-Tobias Arkenau, Iñaki F. Trocóniz, Andrea Varga, Monica Binaschi, Javier Garcia Corbacho, Mario Campone
Publikováno v:
Journal of Clinical Oncology. 37:TPS1101-TPS1101
TPS1101 Background: MEN1611 is a potent, selective class I inhibitor of PI3K, a key enzyme in the transduction of various extracellular growth factor signals essential for cell survival and apoptosis. The discovery in human cancers of frequent PIK3CA
Autor:
William Dott, Carlos Caldas, James D. Brenton, Sanjeev Kumar, Maricica Zabrautanu, Hedley Carr, Nitzan Rosenfeld, Francesco Marrass, Javier Garcia-Corbacho, Mirela Hategan, Brian Dougherty, James Anthony Morris, Richard D. Baird, Davina Gale, Duncan I. Jodrell, Florent Mouliere, Elizabeth A. Harrington, J. Carl Barrett, Bristi Basu, Simon Pacey
Publikováno v:
Journal of Clinical Oncology. 34:11530-11530
11530Background: Serial analysis of plasma ctDNA with next generation sequencing could be used to identify patients for matched molecular therapies, to monitor the relative abundance of mutations o...